

PRESSURE BIOSCIENCES INC

Form 8-K

September 20, 2004

[QuickLinks](#) -- Click here to rapidly navigate through this document

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**Current Report Pursuant  
to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **September 14, 2004**

**PRESSURE BIOSCIENCES, INC.**

(Exact Name Of Registrant As Specified In Its Charter)

**MASSACHUSETTS**

(State or Other Jurisdiction of Incorporation)

**0-21615**

(Commission File Number)

**04-2652826**

(I.R.S. Employer Identification No.)

**375 West Street, West Bridgewater, MA**

(Address of Principal Executive Offices)

**02379**

(Zip Code)

**(508) 580-1900**

(Registrant's Telephone Number, Including Area Code)

**BOSTON BIOMEDICA, INC.**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Item 2.01 Completion of Acquisition or Disposition of Assets.**

On September 14, 2004, Boston Biomedica, Inc. (the "Company") completed the sale of substantially all of the assets and selected liabilities of its BBI Diagnostics and BBI Biotech Divisions to SeraCare Life Sciences, Inc. of Oceanside, California ("SeraCare"), pursuant to an Asset Purchase Agreement between the Company, BBI Biotech Research Laboratories, Inc. ("BBI Biotech") and SeraCare dated April 16, 2004 (the "Asset Purchase Agreement"), for a purchase price of \$30 million in cash of which \$27.5 million was paid at the closing and the remaining \$2.5 million was deposited in escrow pursuant to an escrow agreement expiring in March 2006. The purchase price is subject to increase or decrease on a dollar-for-dollar basis if the net asset value (as defined in the Asset Purchase Agreement) of the assets sold as of the closing date is greater or less than \$8.5 million. The transaction was approved by the Company's stockholders at a special meeting of stockholders held on September 14, 2004.

The assets sold included all accounts and notes receivable, contract rights, owned and leased real property, fixtures and equipment, inventory, intellectual property and books and records that relate to the BBI Diagnostics and BBI Biotech business units (such business units are referred to herein as the "BBI Core Businesses"). The assets sold include the owned real property located at 375 West Street, West Bridgewater, MA. The Company retained all of its assets not relating to the BBI Core Businesses, including: all assets relating to the Company's pressure cycling technology activities; intercompany receivables and payables; a \$1.0 million loan receivable plus accrued interest from Richard T. Schumacher, the Company's Chief Executive Officer and a director; its passive stock ownership interest in Panacos Pharmaceuticals, Inc.; its 30% ownership interest in Source Scientific, LLC, a newly formed limited liability company which recently purchased substantially all of the assets of BBI's Source Scientific business unit; and all of its cash and cash equivalents.

The terms of the transaction were determined by arms-length negotiations between the Company, BBI Biotech, and SeraCare. On April 16, 2004, William Blair & Company, LLC, an independent financial advisor, delivered its opinion that, as of that date, based upon and subject to the various considerations set forth in its opinion, the aggregate payment of \$30 million for the assets and selected liabilities of the BBI Core Businesses, as it may be adjusted in accordance with the Asset Purchase Agreement, was fair, from a financial point of view, to the Company.

In connection with the transactions contemplated by the Asset Purchase Agreement, at the stockholders meeting held on September 14, 2004, the Company's stockholders also approved an amendment to the Company's Restated Articles of Organization to change the Company's name to Pressure BioSciences, Inc. The Articles of Amendment to change the Company's name to Pressure BioSciences, Inc. became effective on September 14, 2004. In connection with the name change, effective on September 16, 2004, the Company also changed its trading symbol on the Nasdaq National Market to "PBIO".

Following the closing of the sale to SeraCare, the Company's operations consist primarily of its pressure cycling technology (PCT) operations. Pursuant to a transition services agreement entered into between SeraCare and the Company at the closing, SeraCare has agreed to provide the Company with access to specified office space at the Company's former facilities located in West Bridgewater, MA and Gaithersburg, MD and the use of certain laboratory equipment in Gaithersburg, MD, each for a period of one year following the closing. The Company will also have limited access to the services of certain of SeraCare's employees for a period of one year following the closing.

As previously announced, the Company intends to commence a tender offer to purchase up to 6,000,000 shares of its common stock at a price of \$3.50 per share shortly following the completion of the sale to SeraCare. The Company expects to use up to \$21.0 million of the after-tax net proceeds from the sale to SeraCare to purchase shares of its common stock tendered in the tender offer.

## Edgar Filing: PRESSURE BIOSCIENCES INC - Form 8-K

The Company's press release announcing the above-described transactions is attached hereto as Exhibit 99.1 and is hereby incorporated herein by reference in its entirety.

### **Important Information Regarding Potential Tender Offer**

This Current Report on Form 8-K does not constitute an offer to buy or the solicitation of an offer to sell shares of common stock of the Company. The Company has not yet commenced the intended tender offer described herein. The Company intends to commence a tender offer in the coming weeks and such tender offer will only be made pursuant to an offer to purchase and other related materials filed with the SEC and which will be distributed to stockholders. You should read these documents if and when they become available because they will contain important information about the tender offer. You may obtain the offer to purchase and other relevant documents that are filed with the SEC when they are available on the SEC's website at [www.sec.gov](http://www.sec.gov). Please contact the Company if you would like to receive the offer to purchase and other related documents at no charge if and when they become available. You may call the Company at (508) 580-1900 or write to the Company at: Pressure BioSciences, Inc., 375 West Street, West Bridgewater, MA 02379.

### **Forward Looking Statements**

Statements contained in this Current Report on Form 8-K regarding the Company's intentions, hopes, beliefs, expectations or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include statements relating to: the amount of any adjustment to the purchase price received from the sale to SeraCare; the anticipated benefits and synergies of the transaction with SeraCare; the Company's expected use of the proceeds from the sale, including its intention to commence a tender offer following the closing of the sale to SeraCare on the terms described herein; the timing of the introduction of the commercial release of the Company's new bench top PCT instrument; and the Company's ability to successfully operate its remaining operations following the closing of the sale to SeraCare. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: the risks associated with acquisitions and dispositions; the risk that the timing and amount of the tender offer purchase price may differ from what is presently anticipated or that the tender may not be able to be completed at all due to unanticipated events or other circumstances beyond the Company's control, including unforeseen liabilities or contingencies reducing the amount of proceeds available for the tender offer; the Company's costs of completing the sale of its BBI Diagnostics and BBI Biotech business units may exceed management's estimates; the Company's ability to attract and retain qualified personnel; fluctuations in the Company's financial and operating results; uncertainties inherent in the development of new products, including the Company's new bench top PCT instrument, including technical risks, cost overruns and delays; the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated; changes in the Company's liquidity and capital resources; declines in the market price of the Company's common stock; changes in the capital markets; competition; general and industry-specific economic conditions; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2003, the Company's definitive proxy statement for its special meeting of stockholders held on September 14, 2004 and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this Current Report on Form 8-K, except as otherwise required by law. Copies of these documents may be obtained by contacting the Company or the SEC at [www.sec.gov](http://www.sec.gov).

**Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.**

Effective on September 14, 2004, concurrent with the closing of the sale of assets to SeraCare described in Item 2.01 above, Kevin W. Quinlan, the Company's President, Chief Operating Officer and Treasurer, resigned from all of such offices. On that same date, Mr. Richard T. Schumacher, the Company's Chief Executive Officer, was appointed to replace Mr. Quinlan as President and Treasurer of the Company. Mr. Quinlan and Mr. Schumacher each continue to serve as a director of the Company.

Mr. Schumacher is the founder of the Company and has served as a director of the Company since 1978. He has most recently served as Chief Executive Officer of the Company since April 16, 2004, and previously served as Chief Executive Officer and Chairman of the Board of the Company from 1992 to February 2003. From July 9, 2003, he served as a consultant to the Company pursuant to a consulting agreement with the Company. He served as President of the Company from 1986 to August 1999. Mr. Schumacher served as the Director of Infectious Disease Services for Clinical Sciences Laboratory, a New England-based medical reference laboratory, from 1986 to 1988. From 1972 to 1985, Mr. Schumacher was employed by the Center for Blood Research, a nonprofit medical research institute associated with Harvard Medical School. Mr. Schumacher received a B.S. in Zoology from the University of New Hampshire.

As described above, on July 9, 2003, Mr. Schumacher agreed to accept an engagement with the Company as a consultant to advise the Company with respect to the strategic direction of the Company's PCT and BBI Source Scientific activities and the Company's ownership interest in Panacos Pharmaceuticals, Inc., effective June 30, 2003. As part of this engagement, Mr. Schumacher continued to reevaluate the ongoing business prospects for both the Company's Laboratory Instrumentation segment and PCT activities.

On February 9, 2004, the Company announced it had extended Mr. Schumacher's consulting agreement until December 31, 2004. Under the terms of the consulting agreement, Mr. Schumacher served in an advisory role directing the Company's PCT and BBI Source Scientific activities, the Company's interest in Panacos Pharmaceuticals, Inc. and such other duties as the President or the Board of Directors of the Company assigned to him. In connection with his consulting agreement, Mr. Schumacher was being paid an annualized salary of \$250,000. In addition to his salary and reimbursement for business related travel expenses, Mr. Schumacher was entitled to receive, in the discretion of the Company's Board of Directors, a bonus in an amount to be determined by the Board of Directors in recognition of the successful completion of his duties and responsibilities under the agreement, and he was also eligible to participate in the Company's health and medical insurance, disability insurance, group life insurance and group travel insurance, and 401(k) retirement plans. When Mr. Schumacher was reappointed as Chief Executive Officer of the Company on April 16, 2004, he continued to receive the same salary and benefits previously provided to him under the consulting agreement.

**Item 9.01 Financial Statements and Exhibits**

- (a) *Financial Statements of the Businesses Acquired.* None.
- (b) *Pro Forma Financial Statements*

Pro forma financial information reflecting the sale of the BBI Core Businesses begins on page 6 of this Current Report on Form 8-K.

Edgar Filing: PRESSURE BIOSCIENCES INC - Form 8-K

(c) *Exhibits*

| <b>Exhibit Number</b> | <b>Exhibit Description</b>   |
|-----------------------|--|
| 2.1                   | Asset Purchase Agreement dated April 16, 2004, by and between the Company, BBI Biotech Research Laboratories, Inc. and SeraCare Life Sciences, Inc. (incorporated by reference from Exhibit 1 of the Company's Current Report on Form 8-K filed with the SEC on April 16, 2004). |
| 2.2                   | Amendment No. 1 to Asset Purchase Agreement dated July 20, 2004, by and between the Company, BBI Biotech Research Laboratories, Inc. and SeraCare Life Sciences, Inc.  |
| 2.3                   | Extension Agreement dated August 6, 2004, by and between the Company, BBI Biotech Research Laboratories, Inc. and SeraCare Life Sciences, Inc.   |
| 99.1                  | Press Release dated September 15, 2004 announcing the disposition.   |

**BOSTON BIOMEDICA, INC.**  
**UNAUDITED PRO FORMA CONDENSED CONSOLIDATED**  
**STATEMENT OF OPERATIONS**  
**FOR THE YEAR ENDED DECEMBER 31, 2003**

|  | Consolidated<br>Boston<br>Biomedica, Inc.<br>as reported<br>December 31,<br>2003 | Less<br>Adjusted<br>BBI Diagnostics<br>Excluding PCT<br>Activities<br>and<br>Intercompany<br>Sales<br>from BBI<br>Diagnostics<br>to other BBI<br>Entities | Less<br>Adjusted<br>BBI Biotech<br>Research<br>Laboratories,<br>Inc.<br>Excluding PCT<br>Activities<br>and<br>Intercompany<br>Sales<br>from BBI Biotech<br>to other<br>BBI Entities | Pro Forma<br>Adjustments<br>and<br>Reclassifications | Foot-<br>note | Pro Forma<br>Subtotal<br>Corp., BBI<br>BioSeq,<br>BBI Source<br>Scientific,<br>and Source<br>Scientific, LLC | Foot-<br>Note | Adjusted<br>Pro Forma<br>Subtotal<br>Corp., BBI<br>BioSeq,<br>BBI Source<br>Scientific,<br>and Source<br>Scientific,<br>LLC<br>Note 8 |
|--|--|---|---|--|---------------|--|---------------|---|
| <b>REVENUE:</b>  |  |   |   |  |               |  |               |   |
| Products   | \$ 13,607,808  | \$ 11,927,122.00  | \$ 158,100.00   | \$ 103,477.00  | 1,5           | \$ 1,626,063.00  |               | \$ 102,396  |
| Services   | 9,687,882  | 130,773   | 8,867,120   | (22,361)   | 1,5           | 667,628  |               | 568,605   |
| Total revenue  | 23,295,690   | 12,057,895  | 9,025,220   | 81,116   |               | 2,293,691  |               | 671,001   |
| <b>COSTS AND EXPENSES:</b>   |  |   |   |  |               |  |               |   |
| Cost of products   | 7,262,815  | 5,646,488   | 246,980   | 108,583  | 1,5           | 1,477,930  |               | 65,781  |
| Cost of services   | 7,602,321  | 47,097  | 7,093,179   | (285,096)  | 1,5           | 176,949  |               |   |
| Research and development   | 1,816,273  | 287,402   | 245,067   | 150,830  | 1,5           | 1,434,634  |               | 1,267,864   |
| Selling and marketing  | 3,282,538  | 2,731,271   | 19,141  | (89,049)   | 5             | 443,077  |               | 411,504   |
| General and administrative   | 4,345,643  | 1,534,362   | 1,583,149   | 884,429  | 2,3,6,7       | 2,112,561  | 7             | 1,484,208   |
| Total operating costs and expenses   | 24,309,590   | 10,246,620  | 9,187,516   | 769,697  |               | 5,645,151  |               | 3,229,357   |
| Operating income (loss)  | (1,013,900)  | 1,811,275   | (162,296)   | (688,581)  |               | (3,351,460)  |               | (2,558,356)   |
| Other operating credits and charges, net (Note 8)                                  |  |   |   |  |               |  |               | (793,104)   |
| Net Interest Expense (income)  | 271,892  | 232,539   | 4,808   |  |               | 34,545   |               | 34,545  |
| Income (Loss) before income taxes  | (1,285,792)  | 1,578,736   | (167,104)   | (688,581)  |               | (3,386,005)  |               | (3,386,005)   |
| Benefit from (Provision for) income taxes  | (3,430)  | (601,819)   | 67,299  | (249,258)  | 4             | 281,831  |               | 281,831   |
| Net income (loss) FROM CONTINUING OPERATIONS*                                      | \$ (1,289,222)   | \$ 976,917  | \$ (99,805)   | \$ (937,839)   |               | \$ (3,104,174)   | *             | \$ (3,104,174)  |
| *EXCLUDES \$135,000 GAIN FROM DISCONTINUED OPERATIONS CLINICAL LABORATORY SEGMENT. |  |   |   |  |               |  |               |   |
| Net loss per share, basic & diluted, from continuing operations                    | \$ (0.19)  |   |   |  |               | \$ (0.46)  |               | \$ (0.46)   |
| Number of shares used to calculate net loss per share, basic and diluted           | 6,810,660  |   |   |  |               | 6,810,660  |               | 6,810,660   |

## Edgar Filing: PRESSURE BIOSCIENCES INC - Form 8-K

---

1. PCT related sales (and associated expenses) to third party entities made by the various entities being sold, and reclassifications.
2. Add back allocated corporate overhead which is included in the results of operations for BBI Diagnostics and BBI Biotech Research Laboratories, Inc.
3. Deduct certain corporate overhead properly assignable to BBI Diagnostics for General Manager, Human Resource and Information Technology functions.
4. Boston Biomedica, Inc. consolidated results of operations reflect the establishment of a full valuation allowance for deferred tax assets.
5. Add back: intercompany sales made by BBI BioSeq to other BBI entities not already eliminated in Note 1 above which would now be considered "third party sales" instead of intercompany sales.
6. Add back allocated corporate overhead that is included in the results of operations for BBI Source Scientific.
7. Pro Forma G & A expenses are based on allocations of actual expenses incurred by a much larger organization and accordingly may not be indicative of a much smaller company .
8. Reflects the net effect of Source Scientific, LLC operating loss of (\$793,104) combined into one line item.



**BOSTON BIOMEDICA, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
(Unaudited)

|   | Consolidated<br>Boston<br>Biomedica, Inc.<br>as Reported<br>Six Months Ended<br>June 30, 2004 | Pro Forma<br>Adjustments<br>for Sale of<br>of BBI Diagnostics<br>and BBI Biotech<br>Research<br>Laboratories, Inc. | Pro Forma<br>Boston<br>Biomedica, Inc.<br>Adjusted<br>Six Months Ended<br>June 30, 2004 |
|---|---|--|---|
| <b>REVENUE:</b>   |   |  |   |
| PCT Products  | \$ 10,556   |  | \$ 10,556   |
| Grant Revenues  | 225,536   |  | 225,536   |
| Total revenue   | 236,092   |  | 236,092   |
| <b>COSTS AND EXPENSES:</b>  |   |  |   |
| Cost of products  | 35,019  |  | 35,019  |
| Research and development  | 432,771   |  | 432,771   |
| Selling and marketing   | 125,880   |  | 125,880   |
| General and administrative  | 622,000   |  | 622,000   |
| Total operating costs and expenses  | 1,215,670   |  | 1,215,670   |
| Operating loss from continuing operations   | (979,578)   |  | (979,578)   |
| Other operating credits and (charges), net (Note 1)   | (302,996)   |  | (302,996)   |
| Interest income   | 3,538   |  | 3,538   |
| Interest expense  | (50,970)  |  | (50,970)  |
| Loss from continuing operations before income taxes   | (1,330,006)   |  | (1,330,006)   |
| Income tax benefit  | 244,036   |  | 244,036   |
| Loss from continuing operations   | (1,085,970)   |  | (1,085,970)   |
| Discontinued operations (Note 2)  |   |  |   |
| Income from discontinued operations (net of taxes)  | 581,159   | (581,159)  |   |
| Net loss  | \$ (504,811)  |  | \$ (1,085,970)  |
| Loss per share from continuing operations, basic & diluted                                    | \$ (0.16)   |  | \$ (0.16)   |
| Income per share from discontinued operations, basic & diluted                                | \$ 0.09   |  |   |
| Net loss per share, basic & diluted   | \$ (0.07)   |  | \$ (0.16)   |
| Weighted average number of shares used to calculate income (loss) per share basic and diluted | 6,836,337   |  | 6,836,337   |

**BOSTON BIOMEDICA, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(Unaudited)

|  | Consolidated<br>Boston<br>Biomedica, Inc.<br>as Reported<br>June 30,<br>2004 | Pro Forma<br>Adjustments<br>for Sale of<br>BBI Diagnostics<br>and BBI Biotech<br>Research<br>Laboratories, | Pro Forma<br>Boston<br>Biomedica, Inc.<br>Adjusted<br>June 30,<br>2004 |
|--|--|--|--|
| <b>ASSETS</b>  |  |  |  |
| <b>CURRENT ASSETS:</b>   |  |  |  |
| Cash and cash equivalents (Note 1)                                       | \$ 425,984   | \$ 27,500,000  | \$ 27,925,984  |
| Marketable securities  | 3,827  |  | 3,827  |
| Accounts receivable, net of allowances of \$250 and \$0,<br>respectively | 31,097   |  | 31,097   |
| Inventories  | 282,112  |  | 282,112  |
| Prepaid expenses and other current assets                                | 52,461   |  | 52,461   |
| Restricted cash  | 33,049   |  | 33,049   |
| Assets held for sale (Note 2)  | 13,944,887   | (13,944,887)   |  |
|  | <u>14,773,417</u>  |  | <u>28,328,530</u>  |
| Property and equipment, net  | 64,937   |  | 64,937   |
| <b>OTHER ASSETS:</b>   |  |  |  |
| Acquired PCT patent costs, net   | 498,506  |  | 498,506  |
| Restricted cash amount held in escrow (Note 3)                           |  | 2,500,000  | 2,500,000  |
| Assets transferred under contractual arrangements (Note 4)               | 1,257,613  |  | 1,257,613  |
| Deferred costs (Note 5)  | 556,985  | (410,000)  | 146,985  |
| Other long-term assets   | 9,178  |  | 9,178  |
|  | <u>2,322,282</u>   |  | <u>4,412,282</u>   |
| <b>TOTAL ASSETS</b>  | <u>\$ 17,160,636</u>   |  | <u>\$ 32,805,749</u>   |
| <b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>                              |  |  |  |
| <b>CURRENT LIABILITIES:</b>  |  |  |  |
| Accounts payable (Note 6)  | \$ 359,337   | \$ 6,500,000   | \$ 6,859,337   |
| Accrued employee compensation  | 163,553  |  | 163,553  |
| Other accrued expenses   | 310,712  |  | 310,712  |
| Liabilities from discontinued operations (Note 7)                        | 57,894   |  | 57,894   |
| Line of Credit   | 523,897  |  | 523,897  |
| Liabilities held for sale (Note 8)                                       | 5,312,012  | (5,312,012)  |  |
| Deferred revenue and other current liabilities                           | 2,700  |  | 2,700  |
|  | <u>6,730,105</u>   |  | <u>7,918,093</u>   |
| <b>LONG-TERM LIABILITIES:</b>  |  |  |  |
| Liabilities from discontinued operations (Note 7)                        | 95,000   |  | 95,000   |
| Liabilities transferred under contractual arrangements (Note 9)          | 360,800  |  | 360,800  |
| Other liabilities  |  |  |  |
|  | <u>455,800</u>   |  | <u>455,800</u>   |

Edgar Filing: PRESSURE BIOSCIENCES INC - Form 8-K

|  | Consolidated<br>Boston<br>Biomedica, Inc.<br>as Reported<br>June 30,<br>2004 | Pro Forma<br>Adjustments<br>for Sale of<br>BBI Diagnostics<br>and BBI Biotech<br>Research<br>Laboratories, | Pro Forma<br>Boston<br>Biomedica, Inc.<br>Adjusted<br>June 30,<br>2004 |
|--|--|--|--|
| Total Liabilities  | 7,185,905  |  | 8,373,893  |
| <b>STOCKHOLDERS' EQUITY:</b>   |  |  |  |
| Common stock, \$.01 par value; 20,000,000 shares authorized;<br>6,836,337 issued and outstanding 6/30/04 | 68,536   |  | 68,536   |
| Loan receivable from Director and CEO  | (1,000,000)  |  | (1,000,000)  |
| Additional paid-in capital   | 21,952,307   |  | 21,952,307   |
| Accumulated (deficit) earnings (Note 10)   | (11,046,112)   | 14,457,125   | 3,411,013  |
|  | 9,974,731  |  | 24,431,856   |
| <b>TOTAL LIABILITIES &amp; STOCKHOLDERS' EQUITY</b>  | <b>\$ 17,160,636</b>   |  | <b>\$ 32,805,749</b>   |

## Edgar Filing: PRESSURE BIOSCIENCES INC - Form 8-K

- Note 1. Adjustment to record the cash consideration of \$30M for the sale of assets and liabilities to SeraCare (including the \$2.5M held in escrow)
- Note 2. Reflects the assets of BBI Diagnostics and BBI Biotech held for sale to SeraCare
- Note 3. Reflects \$2.5M of the cash consideration held in escrow until March 2006
- Note 4. Reflects the assets of BBI Source Scientific transferred under contractual arrangement
- Note 5. Reflects expense of deferred SeraCare transaction costs
- Note 6. Reflects the costs of the SeraCare transaction
- Note 7. Reflects the costs of the 2002 sale of BBI Clinical Laboratories
- Note 8. Reflects the liabilities of BBI Diagnostics and BBI Biotech held for sale to SeraCare
- Note 9. Reflects the liabilities of BBI Source Scientific transferred under contractual arrangement
- Note 10. Reflects the estimated earnings of the sale of BBI Diagnostics and BBI Biotech to SeraCare

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: September 20, 2004

**BOSTON BIOMEDICA, INC.**

By:           /s/ RICHARD T. SCHUMACHER

---

Richard T. Schumacher, President and Chief Executive Officer

---

**EXHIBIT INDEX**

| <b>Exhibit Number</b> | <b>Exhibit Description</b>   |
|-----------------------|--|
| 2.1                   | Asset Purchase Agreement dated April 16, 2004, by and between the Company, BBI Biotech Research Laboratories, Inc. and SeraCare Life Sciences, Inc. (incorporated by reference from Exhibit 1 of the Company's Current Report on Form 8-K filed with the SEC on April 16, 2004). |
| 2.2                   | Amendment No. 1 to Asset Purchase Agreement dated July 20, 2004, by and between the Company, BBI Biotech Research Laboratories, Inc. and SeraCare Life Sciences, Inc.  |
| 2.3                   | Extension Agreement dated August 6, 2004, by and between the Company, BBI Biotech Research Laboratories, Inc. and SeraCare Life Sciences, Inc.   |
| 99.1                  | Press Release dated September 15, 2004 announcing the disposition.   |

QuickLinks

[BOSTON BIOMEDICA, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS \(Unaudited\)](#)

[BOSTON BIOMEDICA, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS \(Unaudited\)](#)

[SIGNATURE](#)

[EXHIBIT INDEX](#)